Literature DB >> 1916996

Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia.

V J Dzau1, G H Gibbons, R E Pratt.   

Abstract

Angiotensin II has been shown by many investigators to be a potent growth factor for vascular smooth cells in culture as well as in vivo. Depending on the conditions, the response of these cells is either hypertrophy or hyperplasia. These observations have important clinical implications, because it has been shown that angiotensin II participates in the hypertrophic response of the vessel wall during hypertension and the hyperplastic response after balloon angioplasty. Thus, an understanding of the molecular mechanism of these responses is important in the development of potential treatment strategies. This review examines the evidence for the growth-promoting properties of angiotensin II, concentrating on these molecular mechanisms. Hypotheses are presented that may explain the bifunctional effects (hypertrophy versus hyperplasia) of angiotensin II. These hypotheses revolve around the interaction of angiotensin with endothelium- and smooth muscle cell-derived products. These autocrine and paracrine interactions play important roles in the modulation of vascular structure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916996     DOI: 10.1161/01.hyp.18.4_suppl.ii100

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  25 in total

1.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

2.  Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block.

Authors:  L Hein; M E Stevens; G S Barsh; R E Pratt; B K Kobilka; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Angiotensinogen T235 expression is elevated in decidual spiral arteries.

Authors:  T Morgan; C Craven; L Nelson; J M Lalouel; K Ward
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Insulin enhances angiotensin II induced DNA synthesis in vascular smooth muscle cells of the rat.

Authors:  Y Ko; A Sachinidis; A J Wieczorek; M Appenheimer; R Düsing; H Vetter
Journal:  Clin Investig       Date:  1993-05

5.  The effects of anti-hypertensive therapy on the structural, mechanical and metabolic properties of the rat aorta.

Authors:  J F Clark; G K Radda; E A Boehm
Journal:  J Muscle Res Cell Motil       Date:  2000-04       Impact factor: 2.698

6.  CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis.

Authors:  Toshimitsu Okuda; Norimasa Yoshida; Tomohisa Takagi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Yuji Naito; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

7.  Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth.

Authors:  M Akishita; M Ito; J Y Lehtonen; L Daviet; V J Dzau; M Horiuchi
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

Authors:  R Morishita; G H Gibbons; K E Ellison; W Lee; L Zhang; H Yu; Y Kaneda; T Ogihara; V J Dzau
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

Review 10.  The process of atherogenesis--cellular and molecular interaction: from experimental animal models to humans.

Authors:  R Ross; L Agius
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.